UPDATE: Canaccord Genuity Initiates Synageva BioPharma at Buy, $60 PT; Attractive Orphan Platform
Canaccord Genuity initiates its coverage on Synageva BioPharma (NASDAQ: GEVA) with a Buy rating and a price target of $90.
Canaccord Genuity says, "Early but encouraging SBC--102 proof --102 proof--of --of- ofof-concept data: --concept data: The lateonset LAL-D Phase 1/2 trial data presented to date has been impressive – rapid and significant decreases in hepatic enzymes indicate that SBC-102 is having the predicted biochemical role in combating liver abnormalities."
GEVA closed at $38.50 on Friday.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.